Eiger BioPharmaceuticals, Inc. (EIGR) Analysts See $-1.02 EPS

March 13, 2018 - By Henry Gaston

 Eiger BioPharmaceuticals, Inc. (EIGR) Analysts See $ 1.02 EPS

Analysts expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report $-1.02 EPS on March, 22.They anticipate $0.51 EPS change or 33.33 % from last quarter’s $-1.53 EPS. After having $-1.10 EPS previously, Eiger BioPharmaceuticals, Inc.’s analysts see -7.27 % EPS growth. The stock increased 5.59% or $0.5 during the last trading session, reaching $9.45. About 57,308 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has declined 64.64% since March 13, 2017 and is downtrending. It has underperformed by 81.34% the S&P500.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $99.38 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

More notable recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: Prnewswire.com which released: “Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene …” on June 29, 2017, also Seekingalpha.com with their article: “Eiger Bio’s ubenimex flunks mid-stage PAH study” published on January 16, 2018, Nasdaq.com published: “Eiger BioPharmaceuticals Inc. (EIGR) Is Sinking After Phase 2 Study Failed” on January 16, 2018. More interesting news about Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) were released by: Prnewswire.com and their article: “Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results” published on November 09, 2017 as well as Prnewswire.com‘s news article titled: “Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences …” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.